Boehringer In­gel­heim beefs up vet port­fo­lio with GST buy­out; No­var­tis, Aus­tria to in­vest €150M in Eu­ro­pean man­u­fac­tur­ing deal

One year af­ter the Eu­ro­pean launch of Ar­ti-Cell Forte — a stem cell prod­uct used to treat lame­ness in hors­es — Boehringer In­gel­heim has ac­quired Bel­gian vet­eri­nary biotech com­pa­ny Glob­al Stem cell Tech­nol­o­gy (GST) with an eye to ex­pand­ing its port­fo­lio of an­i­mal health drugs.

Boehringer ranked as the world’s sec­ond largest an­i­mal health com­pa­ny in 2019, be­hind New Jer­sey-based Zoetis, with about €19 bil­lion (or $21.7 bil­lion) in to­tal net sales. It ini­tial­ly part­nered with GST in 2018, and the re­sult­ing Ar­ti-Cell Forte was the first vet­eri­nary stem cell med­i­cine to gain mar­ket au­tho­riza­tion from the Eu­ro­pean Com­mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER